Drug Profile
Influenza immune globulin - Emergent BioSolutions
Alternative Names: Anti-influenza immune globulin intravenous (Human); FLU IGIV; Intravenous hyperimmune immunoglobulin; NP 025Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Developer Emergent BioSolutions; National Institute of Allergy and Infectious Diseases; University of Minnesota
- Class Antivirals; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 25 Jul 2022 Discontinued - Phase-II for Influenza A virus infections in Canada (IV)
- 25 Jul 2022 Discontinued - Phase-II for Influenza A virus infections in Puerto Rico (IV)
- 25 Jul 2022 Discontinued - Phase-II for Influenza A virus infections in Spain (IV)